Will the project’s progress and results be publicly reported?
Yes. Token balances, burn activity, trial updates, and ESG impact metrics will be published quarterly, with annual third-party audits and blockchain-verified data for transparency.
How is patient and investor data protected?
Personal data is stored only for the legally required period, then securely deleted. It is never repurposed for marketing or shared with third parties without consent.
What compliance measures are in place?
The project enforces strict KYC/AML checks, complies with all relevant crypto and healthcare regulations, and follows medical advertising laws to avoid unverified claims.
Is the diabets cure treatment safe?
The core ingredient, 5-ALA, is already widely available as a supplement with a strong safety profile. Biozipcode™ delivery aims to further minimize risks by targeting only diseased cells. However, full safety confirmation will come from ongoing clinical trials.
How can patients access the treatment?
Patients will be able to join “Diabetes Cure Tours” in Palau, UAE, or Japan. These medical tourism programs combine treatment with long-term wellness stays and are paid for using GDT (or cash though GDT).
Has this treatment been proven in humans?
A Phase IIa trial has already shown significant improvement in patients with diabetes. The next step is to confirm complete remission in larger multi-country trials.
How does this treatment differ from current diabetes care?
Unlike conventional treatments that focus on blood sugar management, this therapy aims to eliminate the root cause of diabetes—abnormal stem cells—offering the potential for complete remission.
What is the roadmap for commercialization?
2026–2027: Multi-site trials in Palau, UAE, and Japan; pilot medical tourism 2028–2029: Phase III trials in UAE, Japan, and the U.S.; regulatory submissions 2030: Global rollout with ~20,000 medical tourism patients annually
How does Biozipcode™ improve treatment safety?
Biozipcode™ uses a unique 7-amino-acid “cell postal code” that delivers drugs only to the intended target cells, preventing exposure to healthy tissues. This greatly reduces side effects while maintaining high efficacy.
What medical innovation is this project pursuing?
The project aims to prove a complete cure for diabetes by targeting and eliminating abnormal hematopoietic stem cells, known as Diabetes Stem Cells (DSCs), using a combination of HDAC inhibitors, 5-ALA, and Biozipcode™ drug delivery technology.
